RGI-1002

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameRGI-1002
Drug Alias NameRGI-1001 lateral spread (REGiMMUNE)ragweed pollen allergy (REGiMMUNE)RGI-1002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunoglobulin E modulators
TargetsImmunoglobulin E
Therapy Area/IndicationsHypersensitivity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRegimmune Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegimmune Ltd
Active IndicationsN/A
Inactive IndicationsHypersensitivity

Other Information

ATC CodeN/A
Related LinksN/A